Imetelstat sodium

DRUG7 trials

Conditions

Acute Myeloid LeukemiaAnaplastic AstrocytomaAnaplastic EpendymomaAstrocytoma, Grade IIBrain and Central Nervous System TumorsBrainstem TumorsEpendymomaGiant Cell Glioblastoma

Phase 1

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

CompletedNCT01273090

Children's Oncology GroupBrain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder +2

Start: 2011-05-31End: 2013-10-31Updated: 2014-01-30

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Active, not recruitingNCT05371964

Geron CorporationMyelofibrosis

Start: 2022-05-04End: 2028-08-01Updated: 2026-08-26

Phase 2

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

CompletedNCT01256762

Geron CorporationLocally Recurrent or Metastatic Breast Cancer

Start: 2010-11-30End: 2012-12-31Updated: 2016-01-26

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

TerminatedNCT01836549

Pediatric Brain Tumor ConsortiumAnaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II +6

Start: 2013-03-31End: 2016-04-30Updated: 2018-07-20

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

WithdrawnNCT02011126

Children's Oncology GroupHepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer +5

Start: 2014-06-30Updated: 2018-08-07

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Active, not recruitingNCT02598661

Geron CorporationMyelodysplastic Syndromes

Start: 2016-01-12End: 2026-10-13Updated: 2026-07-17

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Active, not recruitingNCT05583552

GCP-Service International West GmbHAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2023-06-05End: 2026-06-01Updated: 2026-05-12

Journal of Clinical Oncology2026-05-28

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

2026-01-22

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

2026-01-12

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.

2025-12-01

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

Blood2025-11-03

A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study

Blood2025-11-03

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Blood2025-11-03

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood2025-11-03

Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).

Journal of Clinical Oncology2025-05-28

IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).

Journal of Clinical Oncology2025-05-28

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Blood2024-11-059 citations

Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)

Blood2024-11-054 citations

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Blood2024-11-051 citations

Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents

Blood2024-11-051 citations

Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.

Journal of Clinical Oncology2024-06-01

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.

2023-12-0179 citations

Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Blood2023-11-022 citations

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Blood2023-11-022 citations

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Blood2023-11-021 citations

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Blood2023-11-02

16 more papers not shown

Imetelstat sodium

Sponsors

Conditions

Phase 1

Phase 2

Related Papers